88 Results
Sort By:
Published on January 22, 2021
A new, targeted approach to the treatment of myeloma silences IRF4, a gene that allows myeloma stem cells and tumor cells to proliferate and survive. Past studies have shown that high IRF4 levels are associated with lower overall survival rates for patients with the disease. In the study “Selective antisense…
Published on December 3, 2020
The Multiple Myeloma Research Foundation (MMRF) and Dana-Farber Cancer Institute said today they will partner to identify markers for a precursor disease to multiple myeloma, high-risk smoldering myeloma (SMM), and develop new treatment strategies designed to delay or prevent progression to active multiple myeloma. MMRF and Dana-Farber have launched a…
Published on June 25, 2020
GNS Healthcare, a precision medicine company leveraging artificial intelligence to model individual patients’ response to drug treatment, have unveiled the first in silico multiple myeloma patient. Called Gemini, the in silico multiple myeloma patient is a computer model of disease progression and drug response at the individual patient level. The…
Published on May 28, 2020
Investigators at GNS Healthcare and several research collaboration partners have published a study identifying the transcription factor PHF19 as a novel marker of aggressive multiple myeloma progression in newly-diagnosed patients. GNS Healthcare and partners said the identification of PHF19 could lead to improvements in how diagnostics developers target the transcription…
Published on March 12, 2020
Patterns of unusual gene activity and gene mutations may lead to a new way to detect newly diagnosed multiple myeloma (NDMM) patients at ultra high-risk for aggressive disease progression and risk of death early in the course of their disease. Those patients had a much poorer survival than average and…
Published on August 9, 2018
Researchers from the Icahn School of Medicine at Mount Sinai say they have developed a RNA and DNA sequencing platform that benefits late-stage and drug-resistant multiple myeloma patients by determining which drugs would work best for them. The team described its methodology (“Precision Medicine for Relapsed Multiple Myeloma on the Basis of…
Published on September 6, 2022
A new computed tomography (CT) technology, first introduced to the clinic last year, has demonstrated superior detection of bone disease associated with multiple myeloma at lower radiation doses than conventional CT, according to a new study published in Radiology, a journal of the Radiological Society of North America (RSNA). The…
Published on June 21, 2017
Adaptive Biotechnologies said today it will partner with Johnson & Johnson’s Janssen Biotech to develop its next-generation sequencing (NGS)-based clonoSEQ Assay as a companion diagnostic in ongoing and future clinical trials assessing Darzalex (daratumumab) in patients with multiple myeloma (MM). The value of the collaboration was not disclosed. The companies…
Published on July 29, 2022
Biosimulation company Certara announced on Thursday that is has entered a two-year collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to develop new biosimulation software aimed at improved CAR T-cell therapy dosing for multiple myeloma patients. “We are very pleased to work with MSK, a leading cancer hospital and research…
Published on April 18, 2024
Machine learning and transcriptomics have been combined to create a computational pipeline to systematically predict patient response to cancer drugs, including resistance emergence, at single-cell resolution. The researchers who built the pipeline, PERCEPTION, say this is the first of its kind. It is not yet “clinic ready,” but they hope…
Published on March 6, 2024
Having recently finalized its blockbuster acquisition of antibody drug conjugate (ADC) pioneer Seagen, Pfizer is tidying up its oncology house and making a conspicuous shift towards more biologics. The oncology market is expected to reach $500B by 2030, and Pfizer wants a big piece of it. Especially as the U.S. is making…
Published on February 6, 2024
William Haseltine In today’s world, artificial intelligence (AI) is playing a crucial role in revolutionizing various industries, including healthcare. A recent study revealed that AI can perform medical interviews and provide diagnoses based on a patient’s medical history, potentially transforming the healthcare industry. This development can…
Published on January 4, 2024
Researchers from the Sylvester Comprehensive Cancer at the University of Miami Miller School of Medicine have shown that providing a pretreatment for cancer patients can reduce the rate of cytokine release syndrome (CRS) associated with immunotherapy treatments. The findings, published today in the journal Blood Cancer Discovery, promise to make…
Published on December 27, 2023
AstraZeneca is acquiring cell therapy developer Gracell Biotechnologies Inc. for $1.2B. Gracell is focused on cancer and autoimmune diseases and, importantly, has a toehold in China. The biotech has ten programs in preclinical or later phases. Its most advanced candidate, GC012F, is in Phase I/II trials in the U.S. and…
Published on December 14, 2023
A new strategy that targets two distinct pathways through which antibodies cause hypersensitivity has shown promise for treating severe allergies, a study suggests. The combination approach targets the production of Immunoglobulin E—a key driver of type 1 hypersensitivity and allergies—while maintaining regular immune responses. The tactic acts not only upon…